China SXT Pharmaceuticals (NASDAQ:SXTC) Raised to Sell at Wall Street Zen

China SXT Pharmaceuticals (NASDAQ:SXTC) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

China SXT Pharmaceuticals Trading Up 6.4%

NASDAQ SXTC opened at $3.00 on Friday. The business’s 50-day moving average price is $136.56 and its two-hundred day moving average price is $196.84. China SXT Pharmaceuticals has a 12 month low of $2.63 and a 12 month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share for the quarter. The business had revenue of $0.31 million for the quarter.

Institutional Trading of China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC boosted its stake in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the quarter. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. Institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.